Imugene Ltd (ASX:IMU) has commenced clinical testing a therapeutic anti-cancer vaccine called HER-Vaxx (IMU131), in HER2+ gastric cancer patients.
HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.
HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US$8.2 billion.
To progress the next steps, Imugene is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.
The halt will remain in place until the opening of trade on Thursday 23rd November 2017, or earlier if an announcement is made to the market.